Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug Administration (FDA) has ...

Participant 01-05 had a baseline visual acuity of 2.2 logMAR with an improvement of 0.5 logMAR reported at one month. Participant 01-06 had a baseline visual acuity of 0.96 logMAR with an improvement ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, will host an Investor Day today where it will highlight ...

Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network ...

The second annual Drug Channels Leadership Forum will gather the U.S. pharmaceutical ecosystem’s top leaders, innovators and policy makers to explore the most pressing strategic challenges and ...

ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company ...

A postal strike in Canada disproportionately threatens the lifeblood of Canadian charities, especially health charities, by blocking trusted fundraising channels and cutting off access to essential ...

Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday ...

The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, ...

Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced ...